Atomo Diagnostics Flags Pascal Test Cassette's Performance in Lumos' Test of Diagnostic Product

MT Newswires Live

Aug 21, 2025

Atomo Diagnostics (ASX:AT1) said that its Pascal test cassette performed "exceptionally well" in US clinical studies supporting a Clinical Laboratory Improvement Amendments (CLIA) waiver submission for a test of Lumos Diagnostics Holdings' (ASX:LDX) product, FebriDx, according to a Thursday Australian bourse filing.

FebriDx secured a 510k clearance from the US Food and Drug Administration using the Pascal cassette and recently completed a CLIA waiver trial and submission to the FDA using the Pascal cassette.

The FebriDx test uses Atomo's Pascal test cassette to deliver improved usability and reliability in point-of-care settings, and Atomo is the exclusive licensor, manufacturer, and supplier of the cassettes to Lumos.

Atomo and Lumos are now in talks regarding the supply of Pascal cassettes for the PHASE agreement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2561451880"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2561451880\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2561451880?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-21 15:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561451880","market":"sh","top_or_hot":-1,"title":"Atomo Diagnostics Flags Pascal Test Cassette's Performance in Lumos' Test of Diagnostic Product","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/AT1.AU\">Atomo Diagnostics</a> (ASX:AT1) said that its Pascal test cassette performed \"exceptionally well\" in US clinical studies supporting a Clinical Laboratory Improvement Amendments (CLIA) waiver submission for a test of <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> Holdings' (ASX:LDX) product, FebriDx, according to a Thursday Australian bourse filing.</p><p>FebriDx secured a 510k clearance from the US Food and Drug Administration using the Pascal cassette and recently completed a CLIA waiver trial and submission to the FDA using the Pascal cassette.</p><p>The FebriDx test uses Atomo's Pascal test cassette to deliver improved usability and reliability in point-of-care settings, and Atomo is the exclusive licensor, manufacturer, and supplier of the cassettes to Lumos.</p><p>Atomo and Lumos are now in talks regarding the supply of Pascal cassettes for the PHASE agreement.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atomo Diagnostics Flags Pascal Test Cassette's Performance in Lumos' Test of Diagnostic Product</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtomo Diagnostics Flags Pascal Test Cassette's Performance in Lumos' Test of Diagnostic Product\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-21 15:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/AT1.AU\">Atomo Diagnostics</a> (ASX:AT1) said that its Pascal test cassette performed \"exceptionally well\" in US clinical studies supporting a Clinical Laboratory Improvement Amendments (CLIA) waiver submission for a test of <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> Holdings' (ASX:LDX) product, FebriDx, according to a Thursday Australian bourse filing.</p><p>FebriDx secured a 510k clearance from the US Food and Drug Administration using the Pascal cassette and recently completed a CLIA waiver trial and submission to the FDA using the Pascal cassette.</p><p>The FebriDx test uses Atomo's Pascal test cassette to deliver improved usability and reliability in point-of-care settings, and Atomo is the exclusive licensor, manufacturer, and supplier of the cassettes to Lumos.</p><p>Atomo and Lumos are now in talks regarding the supply of Pascal cassettes for the PHASE agreement.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLIA","symbol_name":"VERIDIEN CLIMATE ACTION ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2561451880","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561451880","pubTimestamp":1755760026,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Atomo Diagnostics  said that its Pascal test cassette performed \"exceptionally well\" in US clinical studies supporting a Clinical Laboratory Improvement Amendments  waiver submission for a test of Lumos Diagnostics Holdings'  product, FebriDx, according to a Thursday Australian bourse filing.FebriDx secured a 510k clearance from the US Food and Drug Administration using the Pascal cassette and recently completed a CLIA waiver trial and submission to the FDA using the Pascal cassette.The FebriDx test uses Atomo's Pascal test cassette to deliver improved usability and reliability in point-of-care settings, and Atomo is the exclusive licensor, manufacturer, and supplier of the cassettes to Lumos.Atomo and Lumos are now in talks regarding the supply of Pascal cassettes for the PHASE agreement.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLIA":"VERIDIEN CLIMATE ACTION ETF","BK7126":"医疗保健用品","BK7007":"医疗保健设备","AT1.AU":"ATOMO DIAGNOSTICS LTD","LDX.AU":"LUMOS DIAGNOSTICS HOLDINGS L","BK7501":"新冠治疗股"},"translate_title":"Atomo Diagnostics在Lumos诊断产品测试中标记了Pascal测试盒的性能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LDX.AU":0.9,"AT1.AU":0.9,"CLIA":1},"content_text":"Atomo Diagnostics (ASX:AT1) said that its Pascal test cassette performed \"exceptionally well\" in US clinical studies supporting a Clinical Laboratory Improvement Amendments (CLIA) waiver submission for a test of Lumos Diagnostics Holdings' (ASX:LDX) product, FebriDx, according to a Thursday Australian bourse filing.FebriDx secured a 510k clearance from the US Food and Drug Administration using the Pascal cassette and recently completed a CLIA waiver trial and submission to the FDA using the Pascal cassette.The FebriDx test uses Atomo's Pascal test cassette to deliver improved usability and reliability in point-of-care settings, and Atomo is the exclusive licensor, manufacturer, and supplier of the cassettes to Lumos.Atomo and Lumos are now in talks regarding the supply of Pascal cassettes for the PHASE agreement.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}